*
*Wilms' tumor|302849000
*
*
or
*
*nephroblastoma|302849000
*
*
is
cancer|363346000|372087000
of the kidneys|64033007|17373004
that typically
occurs|272120004
in children,|410601007|160499008
rarely|103356009
in adults.|133936004

Its common name|72906007
is
an eponym,
referring|439980006
to Dr.|309343006

Max Wilms,
the German surgeon|7695005|304292004
(1867?1918
)
who first
described
this kind|261664005
of tumor.[2]|108369006

Approximately 500 cases|26175008|398241000|26175008|413769002
are
diagnosed|439401001
in the U.S.|223688001

annually.|53281000

The majority
(75%
)
occur|272120004
in otherwise normal children|17621005|410601007|17621005|160499008|258744000|410601007|258744000|160499008
;
a minority|410599005|255606000
(25%
)
are
associated|47429007
with other developmental abnormalities.|74964007|276654001

It
is
highly responsive|75540009|80074009
to treatment,|276239002|416118004
with about 90%|264705001|264703008
of patients|116154003
surviving
at least five years.|276139006|421820001|258707000|263796003|421820001|258707000

Most nephroblastomas|302849000
are
unilateral,|66459002
being
bilateral|51440002
in less|276139006|263796003
than 5%|264706000|264605009
of cases,|398241000|413769002
although
patients|116154003
with Denys-Drash syndrome mostly|236385009
have
bilateral|51440002
or
multiple tumors.|369755005

They
tend
to
be
encapsulated|59135002
and
vascularized tumors|255451006|108369006
that
do
not
cross|65145006
the midline|399488007|260528009
of the abdomen.|277112006|52731004|302553009

In cases|398241000|413769002
of metastasis|128462008
it
is
usually
to the lung.|39607008|181216001

A rupture|415747007
of Wilms' tumor|302849000
puts
the patient|116154003
at risk|410519009
of hemorrhage|131148009
and
peritoneal dissemination|15425007|65709003|264143006|65709003
of the tumor.|108369006

In such cases,|398241000|413769002
surgical intervention|83578000
by a surgeon|304292004
who
is
experienced
in the removal|118292001|128303001
of such
a fragile tumor|59955000|108369006
is
imperative.

Pathologically,
a triphasic nephroblastoma|45906009|302849000
comprises
three elements|421291004|57795002
:

Wilms' tumor|302849000
is
a malignant tumor|363346000|372087000
containing|42504009
metanephric blastema,|361529008
stromal
and
epithelial derivatives.

Characteristic
is
the presence|386397008
of abortive tubules|95568003|13336003
and
glomeruli|68288006
surrounded|355648006
by a spindled cell stroma.|4421005|362837007

The stroma
may
include|55919000
striated muscle,|127954009|118252003
cartilage,|61496007
bone,|272673000|3138006|90780006|128530007
fat tissue,|38888009
fibrous tissue.|34433006

The tumor|108369006
is
compressing|37204000
the normal kidney parenchyma.|17621005|29704000|258744000|29704000

The mesenchymal component|246093002
may
include|55919000
cells|4421005
showing
rhabdomyoid differentiation.

The rhabdomyoid component|246093002
may
itself
show
features
of malignancy|363346000|372087000
(rhabdomyosarcomatous Wilms
).

Wilms' tumors|302849000
may
be
separated|13184001|263869007
into 2 prognostic groups|260306008|261586004|260306008|160481000
based|418836005
on pathologic characteristics|29458008
:

Typical symptoms
are
:

The first sign|276131009
is
normally
a painless abdominal tumor|255350008|128050000
that
can
be
easily|36203004
felt|285854004
by the doctor.|309343006

An Ultrasound,|359659005
Computed Tomography,|77477000
or
MRI|113091000
are
done
first.|255216001|232714002

A tumor biopsy|108369006|86273004
is
not typically
performed|398166005
due to the chance
of upstaging
the cancer|363346000|372087000
and
seeding
the abdomen|277112006|52731004|302553009
with malignant cells.|88400008

The overall 5-year survival|258707000|259039008
is
estimated to|414135002
be
approximately 90%,|26175008|264705001|26175008|264703008
[4]|260308009
but
for individuals|125676002|385435006
the prognosis|20481000
is
highly dependent|75540009|371154000
on individual staging|125676002|72589006|385435006|72589006
and
treatment.|276239002|416118004

Early removal|264499004|118292001|264499004|128303001
tends
to
promote
positive outcomes.|258758003|394617004|10828004|394617004

Tumor-specific loss-of-heterozygosity (LOH)|108369006|69658003|14556007
for chromosomes 1p|91272006
and
16q
identifies|7882003
a subset
of Wilms' tumor patients|302849000|116154003
who
have
a significantly increased risk|35105006|30207005|260366006|30207005
of relapse|263855007|255318003|58184002
and
death.|419620001|268923008

LOH
for these chromosomal regions|91272006|410673009
can
now
be
used|394850002
as an independent prognostic factor|371153006
together with disease stage to|260760003
target
intensity|103370009
of treatment to|276239002|416118004
risk|30207005
of treatment failure.|276239002|76797004|416118004|76797004

Genome-wide copy number|18470003|90522003|410680006|18470003|90522003|410681005
and
LOH status|263490005
can
be
assessed
with virtual karyotyping|312948004
of tumor cells|252987004
(fresh|261013005
or
paraffin-embedded|422100001
).

Mutations|55446002
of the WT1 gene|302849000|67271001
on chromosome 11 p 13|55401003
are
observed
in approximately 20%|26175008
of Wilms' tumors.|302849000

At least half|276139006|263796003
of the Wilms' tumors|302849000
with mutations|55446002
in WT1 also|302849000
carry|288345009
mutations|55446002
in CTNNB1,
the gene|67271001
encoding
the proto-oncogene beta-catenin.[9]|1496005|52095000|1496005|260989008

A gene|67271001
on the X chromosome,|72837006
WTX,
is
inactivated
in
up to 30%
of Wilms' tumor cases,|302849000|398241000|302849000|413769002
according to research
published
in 2007.[10]

Most cases|398241000|413769002
do
not
have
mutations|55446002
in any
of these genes.[11]|67271001

Staging|72589006
is
determined
by combination|89780004
of imaging studies|363679005|110465008|363679005|224699009|278395004|110465008|278395004|224699009
and
pathology findings|394595002|404684003|394595002
if
the tumor|108369006
is
operable.|76234009

Treatment strategy|276239002|416118004
is
determined
by the stage|21191007|371508000|261612004
:

For stage I Wilms' tumor,|258215001|302849000
1
or
more
of the following criteria|255260001
must
be
met|229057006
:

For Stage II Wilms' tumor,|371508000
1
or
more
of the following criteria|255260001
must
be
met|229057006
:

For Stage III Wilms' tumor,|258224005|302849000
1
or
more
of the following criteria|255260001
must
be
met|229057006
:

Stage IV Wilms' tumor|371508000
is
defined
as the presence|386397008
of hematogenous metastases|128462008
(lung,|39607008|181216001
liver,|10200004|181268008
bone,|272673000|3138006|90780006|128530007
or
brain|12738006|258335003
)
,
or
lymph node metastases|94392001
outside the abdomenopelvic region.|410673009

Stage V Wilms? tumor|371508000
is
defined
as bilateral renal involvement|51440002|64033007|248448006
at the time|410669006
of initial diagnosis.|884001|439401001|884001|232714002|439401001|232714002

Note
:
For patients|116154003
with bilateral involvement,|51440002|248448006
an attempt
should
be
made
to
stage|21191007|371508000|261612004
each side|182353008
according to the above criteria|261183002
(stage I|258215001
to III|257471003
)
on the basis|418836005
of extent|255590007
of disease|64572001
prior to biopsy.|86273004

Statistics
may
sometimes
show
more favorable outcomes|242762006|394617004
for more aggressive stages|242762006|61372001|261612004|242762006|261612004
than
for less ones,|276139006|421379005|263796003|421379005
which
may
be
caused|23981006|134198009
by more aggressive treatment|242762006|61372001|276239002|242762006|61372001|416118004|242762006|276239002|242762006|416118004
and/or
random variability|255226008|255372005
in the study groups.|110465008|261586004|110465008|160481000|224699009|261586004|224699009|160481000

Also,
a stage V tumor|371508000
is
not necessarily worse|230993007|390772001|231877006
than a stage IV tumor.|371508000

People|125676002
of African descent|413464008
have
the highest rates|75540009|371879000
of Wilms' tumor.|302849000

Most instances
of cancer|363346000|372087000
occur|272120004
among children|410601007|160499008
between 3|260313008
to 3.5 years old._[citation|260280001|258707000|70753007
needed|410525008|103325001
_]

M
:
URI|54150009

anat/phys/devp/cell|4421005|362837007

noco/acba/cong/tumr,
sysi/epon,
urte

proc/itvp,
drug|410942007
(G4B,
blte,
urte

M
:
MUS,|223541006|447482001
DF+DRCT

anat (h/n,|89177007|258322007|286551008
u,
t/d,
a/p,
l/phys/devp/hist|258995007|420559008

noco
(m,|258311008
s,|288495006
c/cong
(d/tumr,|876000
sysi/epon,
injr

proc,
drug|410942007
(M1A/3|261927002

